Register or Sign in to Save this opportunity, or Send an Inquiry.
Recombinant Fusion Protein Produced by Fusing Vibrio Vulnificus Flagellin and Pathogenic Antigens and the Mucosal Vaccine Containing the Same as an Active Ingredient_CHONNAM NATIONAL UNIV.
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
Recombinant fusion protein produced by fusing Vibrio vulnificus flagellin and pathogenic antigens and the mucosal vaccine containing the same as an active ingredient
Send an Inquiry

Technology Platform

The core technology of Chonnam University is the method to produce the recombination fusion protein made by fusing the flagelin of vibrio vulnificus that is the vaccine adjuvant and the toll-similar soluble body-5 (TLR-5) drug with the antigen protein of a pathogenic organism and the vaccine for administration to the mucous membrane including it.

Background and unmet needs

Streptococcus pneumoniae is gram positive diplococcus and is the most important pathogen in the infection of the mucous membrane such as pneumonia glue ear of an infant or an adult and in the invasive infection such as meningitis and bacterimia.

The current vaccine adjuvant is the ectotoxin with high enterotoxicity so that researches are ongoing in the direction to reduce toxicity and enhance adjuvaticity. It was reported in the recent clinical test that administering it with the influenza antigen into the nasal cavity increases the occurrence of Bells's palsy.

The vaccine adjuvant-antigen recombination fusion protein with the improved immunity and the vaccine including it were developed by providing the flagelin having the strong effect of the adjuvant for the mucous membrane vaccine as the vaccine adjuvant and the vaccine adjuvant-antigen recombination fusion protein vaccine for the streptococcus pneumoniae having the surface protein A (PspA) of streptococcus pneumoniae as the antigen.

Discovery and Achievements

The recombination fusion protein produced by fusing the vaccine adjuvant with the antigen in the invention significantly increased the generation of the PspA-specific antigens (IgG and IgA) in the serum and the rheum and also showed the excellent protection immunity to a fatal dose of streptococcus pneumoniae.

Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE

Opportunity Contact

Warning: include(js_message_scripts_n2.php) [function.include]: failed to open stream: No such file or directory in /home/pharmalicensing/public_html/detail.php on line 833

Warning: include() [function.include]: Failed opening 'js_message_scripts_n2.php' for inclusion (include_path='.:/usr/lib/php:/usr/local/lib/php') in /home/pharmalicensing/public_html/detail.php on line 833